H L Janssen
Overview
Explore the profile of H L Janssen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
646
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Ree M, van der Meer A, van Nuenen A, de Bruijne J, Ottosen S, Janssen H, et al.
Aliment Pharmacol Ther
. 2015 Oct;
43(1):102-13.
PMID: 26503793
Background: MicroRNA-122 (miR-122) is an important host factor for hepatitis C virus replication. Administration of miravirsen, an anti-miR-122 oligonucleotide, resulted in a dose dependent and prolonged decrease in HCV RNA...
2.
Janssen H, Haustermans K, Balm A, BEGG A
Head Neck
. 2005 Jun;
27(7):622-38.
PMID: 15952198
Background: Hypoxia develops in tumors because of a less ordered, often chaotic, and leaky vascular supply compared with that in normal tissues. In preclinical models, hypoxia has been shown to...
3.
van Nunen A, Janssen H, Wolters L, Niesters H, de Man R, Schalm S
Antiviral Res
. 2001 Oct;
52(2):139-46.
PMID: 11672823
For the treatment of chronic hepatitis B (CHB) two drugs have been licensed world-wide: interferon-alpha (IFN) and lamivudine. Both drugs significantly increase the hepatitis B e-antigen (HBeAg) seroconversion rate, but...
4.
Janssen H, Wijnhoud A, Haagsma E, van Uum S, van Nieuwkerk C, Adang R, et al.
Gut
. 2001 Oct;
49(5):720-4.
PMID: 11600478
Background: Malignancy, hypercoagulability, and conditions leading to decreased portal flow have been reported to contribute to the aetiology of extrahepatic portal vein thrombosis (EPVT). Mortality of patients with EPVT may...
5.
Tang T, Batts K, de Groen P, Van Hoek B, Haagsma E, Hop W, et al.
J Hepatol
. 2001 Oct;
35(3):338-43.
PMID: 11592594
Background/aims: It is unclear whether treatment of patients with Budd-Chiari syndrome (BCS) should be based on liver histology, as large histopathological studies have not been performed. We investigated the relationship...
6.
Lisman T, Leebeek F, Mosnier L, Bouma B, Meijers J, Janssen H, et al.
Gastroenterology
. 2001 Jul;
121(1):131-9.
PMID: 11438502
Background And Aims: The bleeding tendency of patients suffering from cirrhosis is in part ascribed to accelerated fibrinolysis. In this study, the role of the recently discovered inhibitor of fibrinolysis,...
7.
8.
Janssen H
Scand J Gastroenterol Suppl
. 2001 Mar;
(232):69-73.
PMID: 11232496
The aetiology of portal vein thrombosis (PVT) is heterogeneous. Important primary risk factors for PVT are cirrhosis, hepatobiliary malignancies and pancreatitis. Newly discovered thrombotic risk factors, such as latent myeloproliferative...
9.
Heijtink R, Janssen H, Hop W, Osterhaus A, Schalm S
J Med Virol
. 2001 Feb;
63(3):217-9.
PMID: 11170060
Chronic hepatitis B patients with low pre-treatment HBeAg (and HBV-DNA) levels are more likely to respond to interferon-alpha therapy. In retrospect, this low level of HBeAg may have been reached...
10.
Minnema M, Janssen H, Niermeijer P, de Man R
J Hepatol
. 2000 Oct;
33(3):509-12.
PMID: 11020010
A young female, who had been in excellent health and had used third-generation oral contraceptives, was admitted to hospital because of abdominal pain and ascites. Budd-Chiari syndrome (BCS) was diagnosed...